MCRB
Seres Therapeutics, Inc.
There isn't enough reported data to score MCRB yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
MCRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MCRB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MCRB PE Valuation
MCRB has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MCRB Forward outlook
There aren't enough analyst estimates for MCRB to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MCRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.02 | -910% |
| Q2 2026 | -$2.45 | -122% |
| Q1 2026 | -$5.19 | -157% |
| Q4 2025 | $0.64 | +$0.64 |
| Q3 2025 | $0.62 | +$5.02 |
| Q2 2025 | $11.28 | +$34.68 |
| Q1 2025 | $9.15 | +$20.95 |
| Q4 2024 | $0.00 | +$17.71 |
MCRB has swung to a loss: it lost $5.02 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over MCRB on earnings quality, reporting a profit while its opponent remains loss making.
MCRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $593K | +69% |
| Q4 2023 | $64K | -93% |
| Q3 2023 | $310K | -91% |
| Q2 2023 | $126.5M | +10301% |
| Q4 2022 | $975K | -86% |
| Q3 2022 | $3.4M | -97% |
| Q2 2022 | $1.2M | -77% |
| Q1 2022 | $1.5M | -74% |
MCRB's revenue is recovering but still below its 2021 peak: $593,000 last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2724% | +3680 points |
| Q2 2026 | -2890% | N/A |
| Q1 2026 | -5840% | N/A |
| Q4 2025 | -4424% | N/A |
| Q3 2025 | -6404% | N/A |
| Q4 2023 | -61759% | -54754 points |
| Q3 2023 | -15295% | -13578 points |
| Q2 2023 | 39% | +5247 points |
MCRB's operating margin was −2724% last quarter, up 3680 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MCRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over MCRB on profitability, with a higher operating margin.
MCRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -577% |
| Q2 2026 | -$22.4M | -$8.9M |
| Q1 2026 | -$16.4M | -161% |
| Q4 2025 | -$14.7M | +$24.2M |
| Q3 2025 | $2.2M | +$37M |
| Q2 2025 | -$13.5M | +$26.4M |
| Q1 2025 | $26.9M | +$62.2M |
| Q4 2024 | -$39M | +$9.4M |
MCRB has burned cash in almost every quarter: −$64M over the past year, against −$23M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MCRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
MCRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +235K shares |
| 1 year | +14% | +1.2M shares |
| 3 years | +56% | +3.6M shares |
| 5 years | +110% | +5.2M shares |
| Available history | +182% | +6.4M shares |
MCRB has 10M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over MCRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MCRB Net Leverage
MCRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MCRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.9 | Oversold |
MCRB's weekly RSI is 25 (oversold) and its Stochastic is 4 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MCRB PE vs Healthcare Sector
| Metric | MCRB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MCRB has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MCRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.36 | 40% below |
| 20 week MA | $4.08 | 65% below |
| 50 week MA | $7.91 | 82% below |
| 100 week MA | $11.2 | 87% below |
| 200 week MA | $29.8 | 95% below |
MCRB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over MCRB on trend strength, trading above more of its moving averages.
MCRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.0 | $485.6 | +507% |
| 2021 | $485.6 | $183.4 | -62% |
| 2022 | $183.4 | $104.8 | -43% |
| 2023 | $104.8 | $28.0 | -73% |
| 2024 | $28.0 | $17.7 | -37% |
| 2025 | $17.7 | $14.7 | -17% |
| 2026 YTD | $14.7 | $1.41 | -90% |
MCRB has finished five years in a row lower, and it's down 90% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over MCRB on returns for 2026, with the stronger performance.